Cudetaxestat
(Lung Fibrosis)
Phase 2
Ready
Discovering breakthroughs in fibrosis and neurodegeneration
Discovering breakthroughs in fibrosis and neurodegeneration
Discovering breakthroughs in fibrosis and neurodegeneration
Pipeline
We are positioned to build a pipeline across a range of fibrotic and neurodegenerative diseases.
BLD-2184
(Neurodegeneration)
IND Ready
BLD-3051
(Lung Fibrosis, Liver Fibrosis)
Pre-Clinical
Join our team
We are looking for people with the passion and commitment of the values we live by.
Passion and commitment to our mission
Accountability to the team
Integrity in everything we do
Be fearless
Recent News
October 18, 2021
Blade Therapeutics Initiates Additional Phase 1 Clinical Study of Cudetaxestat, a Non-Competitive Autotaxin Inhibitor in Clinical Development for Idiopathic Pulmonary Fibrosis
Event
There are no events currently scheduled.
Bringing life changing and revolutionary treatments to patients with fibrotic and neurodegenerative diseases.